Form 4 for BIAF bioAffinity Technologies, Inc.
Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0001493152-24-004768 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-02 | 2024-01-31 | BIAF | Zannes Timothy P | EVP, Sec, Gen. Counsel | A - Grant | $0.00 | +6,688 | 10.3K | +185% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-31 | A | A | 6,688 | $0.00 | 10,307 | D | — | — | (F1) Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. |